DCM
RLAY icon

Discovery Capital Management’s Relay Therapeutics RLAY Stock Holding History

Discovery Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-31,200
Closed -$698K – 66
2022
Q3 		$698K Buy
+31,200
New +$685K 0.1% 45

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Discovery Capital Management's RLAY Position: Q4 2022 in Review

Discovery Capital Management sold out of Relay Therapeutics (RLAY) in Q4 2022, closing a stake of 31,200 shares — an estimated $698K sold.

Discovery Capital Management first reported a position in RLAY in Q3 2022 and held it in 1 quarter. The position peaked at $698K in Q3 2022. 165 funds tracked by Wall St. Rank hold RLAY as of Q4 2022.

  • Discovery Capital Management reported no remaining Relay Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Discovery Capital Management sold 31,200 Relay Therapeutics shares in Q4 2022, an estimated $698K.
  • Discovery Capital Management first reported a position in Relay Therapeutics in Q3 2022 and held it in 1 quarter.
  • Discovery Capital Management's Relay Therapeutics position peaked at $698K in Q3 2022.
  • 165 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2022.

Based on Discovery Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.